Eaton Corporation plc vs Novavax Inc — how do they compare? Eaton Corporation plc trades at $463.43 (market cap $172.82B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Eaton Corporation plc is far larger — about 131.9× Novavax Inc's market cap, and Eaton Corporation plc pays a 0.99% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ETN | NVAX | |
|---|---|---|
Market Cap | $172.82B | $1.31B |
Sector | Technology | Health |
52-Week High | $459.29 | $11.19 |
52-Week Low | $315.82 | $6.22 |
Enterprise Value | $193.45B | $889.30M |
Dividend Yield | 0.99% | — |
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $463.70, up 4.21% over the past 24 hours, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and is approaching resistance at $467. Fundamentally, the company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 beating estimates of $3.07, and raised its full-year 2026 outlook. Revenue growth is robust, supported by surging data-center demand and a $7 million U.S. Air Force contract for grid security announced on August 6, 2026.
The outlook remains positive given Eaton's exposure to AI-driven power infrastructure spending, but the stock's premium valuation (P/E of 45.31) poses a risk if growth moderates. Analyst consensus is strongly bullish with a $499.75 price target, though investors should monitor execution risks and macroeconomic pressures that could impact the industrial sector.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Trailing returns across standard periods
Latest headlines on both assets
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →